As per this study the Global Pneumococcal Vaccine Market was valued USD 7.99 BN (by revenue) in 2022 and is anticipated to reach USD 12.57 BN by 2030 with a CAGR of 5.83%.
Pneumococcal vaccine helps to protect against pneumococcal infections which are most common in kids. Pneumococcal vaccine is categorized into pneumococcal conjugate vaccine (PCV13) and the pneumococcal polysaccharide vaccine (PPSV23). Pneumococcal conjugate vaccine (PCV13) is given to all infants as a series of four injections the first at 2 months of age, then at 4 months, 6 months, and 12–15 months and PPSV23 vaccines are recommended as additional protection against pneumococcal disease in kids of 2–18 years old who have certain chronic health problems. PCV13 protects against 13 types of pneumococcal bacteria whereas PPSV23 protects against 23 types.
Market Dynamics
Rising efforts by the government in order to provide vaccination around the globe along with the increasing cases of pneumococcal diseases due to causative serotype drives need for vaccines is expected to foster the market growth. Advent of pneumococcal vaccines with wider serotype coverage and rising participation of government and non-profit organization for availability, supply, and distribution of pneumococcal vaccines in the developing region is also expected to augment market growth. Whereas, the high cost of vaccines and the entry of new vaccines are anticipated to limit the market growth.
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter's five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of pneumococcal vaccine.
Market Segmentation
The broad pneumococcal vaccine market has been sub-grouped into product type and distribution channel. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
By Vaccine Type
- Pneumococcal Conjugate Vaccine
- Pneumococcal Polysaccharide Vaccine
By Product Type
- Prevnar 13
- Synflorix
- Pneumovax23
By Distribution Channel
- Distribution Partner Companies
- Non-Governmental Organizations
- Government Authorities
Regional Analysis
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for pneumococcal vaccine in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
Global Pneumococcal Vaccine Market Share by Region (Representative Graph)
The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the Pneumococcal Vaccine market includes Pfizer Inc., CSL Ltd., Serum Institute of India Pvt. Ltd., GSK plc, Merck KGaA. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.